Tau-based therapies in neurodegeneration: opportunities and challenges

Cites (229)

Items 201–229 of 229

1. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β
   Jun Jiang, Zhi-Hao Wang, Min Qu, Di Gao, Xiu-Ping Liu, Ling‐Qiang Zhu, Jian‐Zhi Wang · 2015 · Scientific Reports
2. Ribosylation triggering A lzheimer's disease‐like T au hyperphosphorylation via activation of C a MKII
   Wei Yan, Chanshuai Han, Yujing Wang, Beibei Wu, Tao Su, Ying Liu, Rongqiao He · 2015 · Aging Cell
3. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology
   Lixin Song, Sherry X. Lu, Xuesong Ouyang, Jerry P. Melchor, Julie Lee, Giuseppe Terracina, Xiaohai Wang, Lynn A. Hyde, J. Fred Hess, Eric M. Parker et al. · 2015 · Molecular Neurodegeneration
4. Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer’s Rodent Models
   Yuanyuan Wu, Xiaobin Luo, Xinhua Liu, Deyi Liu, Xiong Wang, Ziyuan Guo, Ling‐Qiang Zhu, Qing Tian, Xifei Yang, Jian‐Zhi Wang · 2015 · Scientific Reports
5. Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A
   Ling Li, Zhirong Liu, Juanfang Liu, Xuhui Tai, Xinghua Hu, Xuedong Liu, Zhongliang Wu, Guangyun Zhang, Ming Shi, Gang Zhao · 2013 · Neurobiology of Disease
6. Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
   Illana Gozes · 2011 · Current Pharmaceutical Design
7. Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau
   D. Xia, J. M. Gutmann, J. Götz · 2016 · Scientific Reports
8. Curcumin improves tau-induced neuronal dysfunction of nematodes.
   T. Miyasaka, Ce Xie, S. Yoshimura, Yuki Shinzaki, Sawako Yoshina, E. Kage-Nakadai, S. Mitani, Y. Ihara · 2016 · Neurobiology of Aging
9. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study
   H. Bea Kuiperij, Alexandra A. M. Versleijen, Marijke Beenes, Nicolaas A. Verwey, Luisa Benussi, Anna Paterlini, Giuliano Gb. Binetti, Charlotte Elisabeth Teunissen, Joost Raaphorst, Helenius Jurgen Schelhaas et al. · 2016 · Journal of Alzheimer s Disease
10. Diaminothiazoles Modify Tau Phosphorylation and Improve the Tauopathy in Mouse Models*
    Xuemei Zhang, Israel Hernández, Damien Rei, Waltraud Mair, Joydev K. Laha, Madison E. Cornwell, Gregory D. Cuny, Li‐Huei Tsai, Judith A. J. Steen, Kenneth S. Kosik · 2013 · Journal of Biological Chemistry
11. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
    James A. Hendrix, Randall John Bateman, H. Robert Brashear, Cynthia D. Duggan, María C. Carrillo, Lisa J. Bain, Ronald Bradley Demattos, Russell G. Katz, Susanne Ostrowitzki, Eric Siemers et al. · 2016 · Alzheimer s & Dementia
12. Pittsburgh Compound‐B (PiB) binds amyloid β‐protein protofibrils
    Ghiam Yamin, David B. Teplow · 2016 · Journal of Neurochemistry
13. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice
    Jin Chu, J. G. Li, Phillip F. Giannopoulos, Benjamin E. Blass, Wayne E. Childers, Magid A. Abou-Gharbia, Domenico Praticò · 2015 · Molecular Psychiatry
14. No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice
    Annika van Hummel, Mian Bi, Stefania Ippati, Julia van der Hoven, Alexander M. Volkerling, Wei S. Lee, Daniel C. S. Tan, André Bongers, Arne Ittner, Yazi Diana Ke et al. · 2016 · PLoS ONE
15. Truncated tau deregulates synaptic markers in rat model for human tauopathy
    Santosh Jadhav, Stanislav Katina, Andrej Kováč, Zuzana Kazmerova, Michal Novák, Norbert Žilka · 2015 · Frontiers in Cellular Neuroscience
16. Stem-cell discovery platforms yield first clinical candidates
    Asher Mullard · 2015 · Nature Reviews Drug Discovery
17. Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent
    Miranda E. Orr, Valentina Rose Garbarino, Angelica Salinas, Rochelle Buffenstein · 2014 · Neurobiology of Aging
18. Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide 1
    Weihong Pan, Beka Solomon, Lawrence M. Maness, Abba J. Kastin · 2002 · Experimental Biology and Medicine
19. Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies
    Sahabudeen Sheik Mohideen, Yasutoyo Yamasaki, Yasuhiro Omata, Leo Tsuda, Yuji Yoshiike · 2015 · Scientific Reports
20. A prospective pilot study on serum cleaved tau protein as a neurological marker in severe traumatic brain injury
    Sharad Pandey, Kulwant Singh, Vivek Sharma · 2017 · British Journal of Neurosurgery
21. Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease
    Michael Hanenberg, Jordan McAfoose, Luka Kulic, Tobias Welt, Fabian Wirth, Petra Parizek, Lisa Strobel, Susann Cattepoel, Claudia B. Späni, Rebecca Derungs et al. · 2014 · Journal of Biological Chemistry
22. Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product
    Lenka Hromádková, Michala Kolarova, Barbora Jankovičová, Aleš Bartoš, Jan Říčný, Zuzana Bı́lková, Daniela Řı́pová · 2015 · Journal of Neuroimmunology
23. Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimer’s Disease
    Scott Counts, Sylvia E. Perez, Bin He, Elliott Jay Mufson · 2014 · Current Alzheimer Research
24. Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors
    Jason D. Katz, Andrew M. Haidle, Kaleen K. Childers, Anna A. Zabierek, James P. Jewell, Yongquan Hou, Michael D. Altman, Alexander A. Szewczak, Dapeng Chen, Andreas Harsch et al. · 2016 · Bioorganic & Medicinal Chemistry Letters
25. Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure
    Asher Mullard · 2016 · Nature Reviews Drug Discovery
26. Activation of Autophagy by Rapamycin Does Not Protect Oligodendrocytes Against Protein Aggregate Formation and Cell Death Induced by Proteasomal Inhibition
    Monika Noack, Christiane Richter‐Landsberg · 2014 · Journal of Molecular Neuroscience
27. Personalised and Precision Medicine in Cancer Clinical Trials: Panacea for Progress or Pandora's Box?
    Mark Lawler, Richard J. Sullivan · 2015 · Public Health Genomics
28. Effects of Tau Domain-Specific Antibodies and Intravenous Immunoglobulin on Tau Aggregation and Aggregate Degradation
    José O. Esteves-Villanueva, Hanna Trzeciakiewicz, David A. Loeffler, Sanela Martić · 2014 · Biochemistry
29. Brain Aggregates: An EffectiveIn VitroCell Culture System Modeling Neurodegenerative Diseases
    Misol Ahn, Franck K. Kalume, Rose Pitstick, Abby Oehler, George A. Carlson, Stephen J. DeArmond · 2016 · Journal of Neuropathology & Experimental Neurology